Low-dose IL-2 study after heart bypass surgery
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether a low dose of a natural immune-boosting protein (IL-2) given after heart bypass surgery can help reduce heart damage. The treatment aims to activate special immune cells that protect heart tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must be scheduled for or have recently had coronary artery bypass grafting (CABG) surgery—a type of heart surgery to improve blood flow
- You cannot have certain heart rhythm problems or severe blockages that make you unstable
- You cannot have autoimmune disease or be taking regular immune-suppressing medications
- You cannot have active infection, HIV, hepatitis, or active cancer requiring treatment
- If you can become pregnant, you cannot be pregnant or breastfeeding, and must use effective birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a supplement called alpha ketoglutarate (AKG) can help older adults recover better after heart bypass surgery. If you are 50 or older and scheduled for elective bypass surgery, you may be able to join.
This trial tests if dexmedetomidine or methylprednisolone is better at reducing inflammation during coronary artery bypass grafting (CABG) with a heart-lung machine. The goal is to find a treatment that helps patients recover better.
This trial tests whether a low dose of colchicine, an anti-inflammatory medication, can help prevent bypass grafts from closing after heart surgery. You would take this medication for a set period after your coronary artery bypass graft (CABG) surgery.
This study is checking on people who finished a previous trial (IVORY) that tested a low-dose treatment called IL-2 for reducing inflammation after a heart attack. It will see how they are doing over time and if the treatment helped their heart health.
This trial tests whether injections of a medicine called interleukin-2 (IL-2) into the tumor before surgery can improve outcomes for people with triple-negative breast cancer. It may help by boosting the body’s immune response, but it also requires frequent hospital visits and careful safety screening.
This study tests if a low dose of IL-2 can help control both lupus and CMV virus in the blood. It aims to see if the treatment improves symptoms and reduces virus levels safely.
Hear when a new Coronary artery disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.